Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences : and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 10:25pm CET

By a News Reporter-Staff News Editor at Pharma Business Week -- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead's cash tender offer for Kite expired at 11:59 p.m. on September 25, 2017 (see also Biotechnology Companies).

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170926005682/en/

On September 8, 2017, Gilead and Kite filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice.

Keywords for this news article include: Gilead Sciences Inc., Biotechnology Companies, Biopharmaceutical Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
11/15 GILEAD SCIENCES : Today’s Research Reports on Trending Tickers: Gilead Sciences ..
11/09 GILEAD SCIENCES : Columnist Shreds Gilead's Lame Excuses for Sky-High Drug Price..
11/09 GILEAD SCIENCES : New Findings in DNA Research Described from Gilead Sciences (D..
11/07 GILEAD SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
11/04 GILEAD SCIENCES : Abraham Brass Receives Grant From Gilead for HIV Research
11/04 GILEAD SCIENCES : Analysts See $2.07 EPS for Gilead Sciences, Inc. (GILD)
11/02 GILEAD SCIENCES : to Present at the Credit Suisse 26th Annual Healthcare Confere..
11/02 GILEAD SCIENCES : New Findings from Gilead Sciences Describe Advances in Antibio..
10/31 Pfizer expects broad interest for consumer health business
10/28 GILEAD SCIENCES INC. : Still Singing the HCV Blues in the 3rd Quarter
More news
News from SeekingAlpha
09:53a Stocks to watch next week
11/17 YOUR DAILY PHARMA SCOOP : Gilead CAR-T Potential, Egalet Surges, Aerie Launches ..
11/16 2017 Cigar Butts More Soggy Than Smoke - Low EV/EBIT Large And Midcap YTD Upd..
11/16 Watch Out Gilead, Juno's Strategy Might Just Pay Off
11/16 INTEGRATED BIOSCI RESEARCH ON ATARA : What's Next After CAR-T?
Financials ($)
Sales 2017 25 806 M
EBIT 2017 15 765 M
Net income 2017 10 588 M
Debt 2017 12 742 M
Yield 2017 2,92%
P/E ratio 2017 9,25
P/E ratio 2018 11,75
EV / Sales 2017 4,16x
EV / Sales 2018 4,71x
Capitalization 94 601 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 84,9 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES1.16%94 601
REGENERON PHARMACEUTICALS6.67%42 072
VERTEX PHARMACEUTICALS100.10%37 280
GENMAB3.15%11 878
EXELIXIS, INC.76.93%7 805
BLUEBIRD BIO INC164.51%7 480